Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.51 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13206731 | 0.88 | PPARA (0.58) | PPARAEPHX2FAAHCNR1HDAC1 | |
| SCHEMBL16984603 | 0.87 | CHRM2 (0.55) | PPARAHDAC1HDAC6CHRM2CHRM1 | |
| SCHEMBL18794618 | 0.85 | PPARA (0.59) | PPARAEPHX2FAAHCNR1PPARG | |
| SCHEMBL21381119 | 0.85 | PPARA (0.68) | PPARAEPHX2FAAHHDAC1HDAC6 | |
| SCHEMBL19021153 | 0.85 | PPARA (0.68) | PPARAEPHX2FAAHHDAC1HDAC6 | |
| SCHEMBL21381118 | 0.85 | PPARA (0.68) | PPARAEPHX2FAAHHDAC1HDAC6 | |
| SCHEMBL26430086 | 0.84 | PPARA (0.55) | PPARAEPHX2FAAHCNR1PPARG | |
| SCHEMBL4449661 | 0.84 | PPARA (0.55) | PPARAEPHX2FAAHCNR1PPARG | |
| SCHEMBL14167525 | 0.83 | HDAC1 (0.57) | PPARAEPHX2FAAHCNR1HDAC1 | |
| SCHEMBL13639167 | 0.83 | HDAC1 (0.57) | PPARAEPHX2FAAHCNR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908826-B2 | Synthetic method | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170174608-A1 | Synthetic Method | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2017-06-22 | — | — | US | disclosed |
| US-20170174608-A1 | Synthetic Method | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2017-06-22 | — | — | US | disclosed |
| WO-2015114323-A1 | SYNTHETIC METHOD | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174608-A1 | Synthetic Method | SQLE, FDFT1, CYP51A1 | PPARA 2617/4885EPHX2 89/4885FAAH 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.